Dobutamine Stress Echocardiography

Clinical, resting echo and dipyridamole stress echocardiography findings for the screening of renal transplant candidates

“…In fact, up to 39% of dialysed patients have history of complex ventricular arrhythmias [15], contraindicating inotropic stress [16]. Moreover, they have high prevalence of systemic hypertension, which has been found to independently predict dobutamine-induced adverse reactions in consecutive series of patients [14].…”

“…Indeed, an excess of dobutamine-induced side-effects has been reported in hypertensive non-uremic subjects [14]. Moreover, dialysed patients are at increased risk for complex ventricular arrhythmias [15], representing a well-known contraindication to adrenergic stress [16]. Dipyridamole has the potential advantage of providing similar prognostic information compared to dobutamine stress echocardiography in non-uremic patients [17] with no hypertensionrelated limitation of feasibility [14].…”

Dipyridamole stress echocardiography in diagnosis and prognosis of hemodialysis patients with asymptomatic coronary disease

“…[11][12][13][14][15] However, the high prevalence of hypertension in ESRD patients and the risk of ventricular arrhythmias may represent a contraindication to the use of adrenergic stress in this population. In nonuremic patients, dipyridamole stress echocardiography (DSE) has a similar prognostic value as compared to dobutamine stress echocardiography, 16,17 but the usefulness of DSE for CAD detection in asymptomatic HD patients remains to be defined.…”